CSBR Stock Forecast: Champions Oncology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.35
−1.14% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$61.2M
Ticker Nerd rank
27/ 100
Median analyst target
—
Analysts covering
—
Revenue$13.8M+12.0% y/y
Operating income−$521K
Net income−$667K
Free cash flow−$2.2M
Quarterly, 7 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−9.6%
YTD
−37.0%
1Y
−34.7%
From 52W high
−44.2%
From 52W low
0.0%
$4.35
$7.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Champions Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
27/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Quality
78
Value
58
Growth
33
Issuance
22
Accruals
21
Revisions
20
Momentum
18

Volatility (78): The share price has been relatively steady.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CSBR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CSBR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26CSBR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2025Craig-HallumMaintainsBuy$8.00 → $12
12 Dec 2024Craig-HallumMaintainsBuy—
12 Sept 2024Craig-HallumUpgradeBuy—
13 Mar 2024Craig-HallumDowngradeHold—
22 Sept 2023Roth MKMMaintainsBuy—
15 Mar 2021Roth CapitalMaintainsBuy—
18 Nov 2019BenchmarkInitiatesSpeculative Buy—
20 Sept 2019Roth CapitalInitiatesBuy—
24 July 2019Janney CapitalDowngradeNeutral—
24 July 2019Janney Montgomery ScottDowngradeNeutral—
17 July 2018Craig-HallumInitiatesBuy—
15 May 2018Dawson JamesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CSBR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CSBR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Champions Oncology, Inc. returned −34.7% against +6.9% for the S&P 500, dividends included.

CSBR vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CSBRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CSBR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.0×

Cheaper than 65% of US stocks

Price / book
15.9×

Cheaper than 4% of US stocks

EV / EBITDA
170.2×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
8.8%

Higher than 51% of US stocks

Earnings growth (YoY)
—
Gross margin
50.8%

Higher than 63% of US stocks

Operating margin
−1.5%

Higher than 33% of US stocks

Net margin
−1.9%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−28.4%

Higher than 29% of US stocks

Return on assets
−1.8%

Higher than 38% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Champions Oncology, Inc. has a market value of $61.2M and an enterprise value of $68.4M.

  • Revenue in the twelve months to 30 Apr 2026: $59.4M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$1.1M, a −1.9% net margin.

  • Free cash flow in the twelve months to 30 Apr 2026: −$5.0M.

  • Shares outstanding: 13.9M.

  • forward P/E: 44.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Champions Oncology, Inc. employs 214 people — $278K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CSBR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CSBRChampions Oncology, Inc.$61.2M27
NTRBNutriband, Inc.$59.8M33
NMRANeumora Therapeutics, Inc.$60.8M35
VTVTvTv Therapeutics, Inc.$61.1M69
NRXSNeurAxis, Inc.$58.3M47
TENXTenax Therapeutics, Inc.$56.9M24
FBIOFortress Biotech, Inc.$63.1M87

Take a look at CSBR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Champions Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CSBR

How does Ticker Nerd's model rank CSBR?

As at 21 Nov 2026, Champions Oncology, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

What is the CSBR stock forecast for 2030?

No analyst covering Champions Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSBR are extrapolating price history, which says nothing about the business.

How has CSBR stock performed over the past year?

Champions Oncology, Inc. returned -34.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Champions Oncology, Inc. do?

Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies.

Company

About Champions Oncology, Inc.

Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies. Its core offerings include proprietary tumor models, in vivo and ex vivo research platforms, biomarker analysis, and the TumorGraft technology platform, which supports more personalized approaches to oncology research. The company also offers Lumin Bioinformatics, a software platform that combines research and clinical data for computational cancer analysis and decision-making support. Champions Oncology serves drug developers, research organizations, and medical professionals through technology-enabled services centered on improving the understanding and development of cancer treatments. Headquartered in Hackensack, New Jersey, Champions Oncology operates as a specialized provider within the broader oncology contract research and life sciences tools market.

CEO Mr. Robert Brainin · 214 employees · United States · https://www.championsoncology.com